Log in
Enquire now
‌

US Patent 10239837 Piperidine derivatives as HDAC1/2 inhibitors

Patent 10239837 was granted and assigned to Regenacy Pharmaceuticals on March, 2019 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors

Contents

Is a
Patent
Patent

Patent attributes

Patent Applicant
Regenacy Pharmaceuticals
Regenacy Pharmaceuticals
Current Assignee
Regenacy Pharmaceuticals
Regenacy Pharmaceuticals
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
Patent Number
10239837
Date of Patent
March 26, 2019
Patent Application Number
15719748
Date Filed
September 29, 2017
Patent Citations Received
‌
US Patent 11702389 Piperidine derivatives as HDAC1/2 inhibitors
0
‌
US Patent 10968180 Piperidine derivatives as HDAC1/2 inhibitors
Patent Primary Examiner
‌
Timothy P Thomas
Patent abstract

Provided herein are compounds, pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat diseases or disorders associated with HDAC1 and/or HDAC2 activity.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 10239837 Piperidine derivatives as HDAC1/2 inhibitors

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.